The Lancet Respiratory Medicine delivers comprehensive, clinically-focused coverage on all areas of respiratory medicine and critical care, including but not limited to: COPD, asthma, cystic fibrosis, IPF, pneumonia, influenza, tuberculosis, sarcoidosis, pulmonary hypertension, sleep medicine, respiratory infections, pulmonary vascular disease, lung cancer, tobacco control, thoracic and reconstructive surgery, mesothelioma, and palliative medicine. Continuing in The Lancet's tradition of publishing high-impact content that influences medical practice, each monthly issue of The Lancet Respiratory Medicine contains Original Research, Reviews, Personal Views, Comments, and News.

The Lancet Respiratory Medicine is stringently edited and peer-reviewed to ensure the scientific merit and clinical relevance of its diverse content. Original Research is fast-tracked to publication within 8 weeks of submission (on average) and published Online First on www.thelancet.com before appearing in print.

Now indexed in PubMed, Journal Citation Reports®, and Scopus, the journal accepts submissions of Original Research, Reviews, Personal Views, and Comments. Visit http://ees.elsevier.com/thelancetrm to learn more about our editorial scope and aims and to submit your manuscript.

Gold or Green Open Access is available for research supported by selected funding agencies with whom Elsevier has an agreement. The journal is also freely available to readers in low-to-middle-income countries via the HINARI programme or via IP access at www.thelancet.com.

To find out more about The Lancet Respiratory Medicine, visit www.thelancet.com/respiratory.